Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
116.35
+4.35 (3.88%)
At close: Nov 18, 2026, 4:00 PM EST
119.87
+3.52 (3.03%)
Pre-market: Nov 19, 2026, 8:37 AM EST
Twist Bioscience Revenue
In the fiscal year ending September 30, 2026, Twist Bioscience had annual revenue of $459.43M with 22.00% growth. Twist Bioscience had revenue of $126.64M in the quarter ending September 30, 2026, with 27.91% growth. That makes Twist Bioscience the 11,751st largest company in the world by revenue and 2,334th in the United States.
Revenue (ttm)
$459.43M
Revenue Growth
+22.00%
P/S Ratio
17.27
Revenue / Employee
$425,401
Employees
1,080
Market Cap
7.93B
Revenue by Geography
- Americas 278.76M 60.7%
- Europe, Middle East and Africa (EMEA) 147.99M 32.2%
- Asia Pacific (APAC) 32.68M 7.1%
Fiscal year ended Sep 30, 2026 See the full Twist Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2026 | 459.43M | 82.86M | 22.00% |
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 1.05B |
| Axsome Therapeutics | 865.27M |
| Mirum Pharmaceuticals | 670.78M |
| Arrowhead Pharmaceuticals | 450.82M |
| Ligand Pharmaceuticals | 253.83M |
| ImmunityBio | 182.57M |
| ABIVAX Société Anonyme | 5.33M |
TWST News
- 1 day ago - Twist Bioscience Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - Twist Bioscience price target lowered to $130 from $215 at Barclays - TheFly
- 3 days ago - Twist Bioscience price target lowered to $120 from $190 at UBS - TheFly
- 5 days ago - Twist Bioscience price target lowered to $175 from $190 at Leerink - TheFly
- 6 days ago - Twist Bioscience price target lowered to $137 from $190 at TD Cowen - TheFly
- 6 days ago - Twist Bioscience price target lowered to $135 from $187 at Baird - TheFly
- 6 days ago - Twist Bioscience price target lowered to $150 from $212 at Guggenheim - TheFly
- 6 days ago - Twist Bioscience price target lowered to $150 from $205 at Canaccord - TheFly